# Sotevtamab

Source: https://onco.cc/drugs/sotevtamab/  
OnCo record `sotevtamab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sotevtamab is a monoclonal antibody from Alethia Biotherapeutics, in registered phase 2 trials for colorectal cancer.

## Summary

Sotevtamab is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Alethia Biotherapeutics, in colorectal cancer. A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Also known as: AB-16B5
- Tags: pipeline; ctgov-ingest; registry-only
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody: the international non-proprietary name stem -mab marks an antibody that binds one target. The registry record does not state the target unless named in the trial entries below.

## Sources

- ClinicalTrials.gov: trials of Sotevtamab: https://clinicaltrials.gov/search?intr=Sotevtamab

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- trials: [Sotevtamab (AB-16B5) Combined With FOLFOX as Neoadjuvant Treatment Prior to Resection of Colorectal Cancer Liver Metastasis](https://onco.cc/trials/nct06225843/)

---
JSON: https://onco.cc/api/v1/entities/sotevtamab.json